This HTML5 document contains 90 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/pubchem-substance/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/iuphar/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/drugbank/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/guide-to-pharmacology/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/national-drug-code-directory/
n11http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/chebi/
n28http://linked.opendata.cz/resource/drugbank/patent/
n31http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/pharmgkb/
n30http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00952/identifier/pubchem-compound/
n19http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00952
rdf:type
n3:Drug
n3:description
Naratriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.
n3:dosage
n7:271B4191-363D-11E5-9242-09173F13E4C5 n7:271B4192-363D-11E5-9242-09173F13E4C5 n7:271B4193-363D-11E5-9242-09173F13E4C5 n7:271B4194-363D-11E5-9242-09173F13E4C5 n7:271B4195-363D-11E5-9242-09173F13E4C5 n7:271B4196-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12463278 # Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16389295 # Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15320857
n3:group
investigational approved
n3:halfLife
5-8 hours
n3:indication
For the acute treatment of migraine attacks with or without aura in adults.
n3:manufacturer
n13:271B418B-363D-11E5-9242-09173F13E4C5 n13:271B418C-363D-11E5-9242-09173F13E4C5 n13:271B4189-363D-11E5-9242-09173F13E4C5 n13:271B418A-363D-11E5-9242-09173F13E4C5 n13:271B4188-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00952 n31:DB00952
dcterms:title
Naratriptan
adms:identifier
n6:Naratriptan n12:DB00952 n14:7478 n15:4287 n21:46507243 n22:PA450597 n23:4440 n24:C07792 n25:0173-0561-00 n26:45 n27:45
n3:mechanismOfAction
Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
n3:packager
n13:271B4184-363D-11E5-9242-09173F13E4C5 n13:271B4185-363D-11E5-9242-09173F13E4C5 n13:271B4183-363D-11E5-9242-09173F13E4C5 n13:271B4186-363D-11E5-9242-09173F13E4C5 n13:271B4187-363D-11E5-9242-09173F13E4C5
n3:patent
n28:4997841
n3:synonym
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide Naratriptanum
n3:toxicity
Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
n3:volumeOfDistribution
* 170 L
n8:hasAHFSCode
n9:28-32-28
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
28%-31% (over the concentration range of 50 to 1000 ng/mL)
n3:synthesisReference
Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Sandip Vasant Chikhalikar, Maruti Ghagare, "Process for the synthesis of naratriptan." U.S. Patent US20120220778, issued August 30, 2012.
foaf:page
n17:ame1018.shtml n29:naratriptan.html n30:naratript.htm
n3:IUPAC-Name
n4:271B419B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B41A1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B41A0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B419D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B419E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B419F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B41B1-363D-11E5-9242-09173F13E4C5 n4:271B4199-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B41B3-363D-11E5-9242-09173F13E4C5 n4:271B4197-363D-11E5-9242-09173F13E4C5 n4:271B419A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4198-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n19:N02CC02
n3:H-Bond-Acceptor-Count
n4:271B41A7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B41A8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B41A2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B41A3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41A5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B41A4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41A6-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
121679-13-8
n3:category
n3:clearance
* 6.6 mL/min/kg
n3:containedIn
n20:271B418D-363D-11E5-9242-09173F13E4C5 n20:271B418F-363D-11E5-9242-09173F13E4C5 n20:271B4190-363D-11E5-9242-09173F13E4C5 n20:271B418E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B41AD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B41AF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B41B0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B41B2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B41AC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B41AB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B41AE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B419C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B41A9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B41AA-363D-11E5-9242-09173F13E4C5